The patients with non-M3 AML with increased RhoBTB1 and RhoBTB3 mRNA expression levels or decreased RhoC and RhoF mRNA expression levels were predicted to have favorable OS. This evidence concerns the gene RHOBTB3 and acute myeloid leukemia.